The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation ...

Barclays downgraded Sarepta (SRPT) to Underweight from Equal Weight with a price target of $10, down from $18. The firm says the suspension of ...

The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.

Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

Currently, a multidistrict litigation against Pfizer (NYSE: PFE) is underway on behalf of women who claim to have developed meningiomas after receiving four or more consecutive injections of ...

The FDA is investigating the death last month of an eight-year-old boy in Brazil who had received Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl)—though the company and its ...

HCA Healthcare raises 2025 profit forecast amidst insurance uncertainty while Centene anticipates a 2026 profitability boost ...